0001213900-26-016860
SEC filingNeuroOne Medical Technologies Corporation reported Q1 2026 results with total revenue of $5.9M, consisting of $2.9M in product revenue and $3.0M in license revenue. The company generated a product gross profit of $1.6M but recorded an operating loss of $1.7M due to total operating expenses of $3.3M. Net loss for the quarter was $1.4M. The balance sheet shows total assets of $8.6M with cash and cash equivalents of $3.6M, while total liabilities stand at $2.2M. Operating activities used $3.1M in cash, resulting in a net decrease in cash of $3.0M for the quarter. The company ended the period with $6.6M in cash. No prior period comparisons are provided in the source data.
NeuroOne Medical Technologies Corporation reported Q1 2026 financial results for the period ending December 31, 2025. The company generated total revenue of $5.9M, comprising $2.9M in product revenue and $3.0M in license revenue. Product gross profit was $1.6M with cost of product revenue at $1.3M. Operating expenses totaled $3.3M, including $1.9M in selling, general and administrative expenses and $1.4M in research and development. This resulted in an operating loss of $1.7M. After accounting for a fair value change in warrant liability of -$223K, financing costs of $325K, and other income of $47K, the company reported a net loss of $1.4M. No prior period comparisons are provided in the source data.
The company's revenue streams consist of two primary components: product revenue and license revenue. Product revenue for Q1 2026 was $2.9M, while license revenue was $3.0M, totaling $5.9M in overall revenue. The source data does not provide segment breakdowns, geographic mix, or growth drivers beyond these two revenue categories. No comparative data from prior periods is available in the provided information to analyze revenue trends or growth patterns.
Product gross profit was $1.6M on product revenue of $2.9M, though the source data does not provide sufficient information to calculate a gross margin percentage. Operating loss was $1.7M on total revenue of $5.9M. The cost structure includes $1.3M in cost of product revenue and $3.3M in total operating expenses, with $1.9M allocated to selling, general and administrative expenses and $1.4M to research and development. No prior period margin data is available for comparison of trends.
Operating activities used $3.1M in cash during the quarter, primarily driven by the net loss of $1.4M and changes in working capital. Investing activities used $41K for property and equipment purchases. Financing activities provided $148K, mainly from warrant exercises of $174K offset by various issuance and financing costs. The net decrease in cash was $3.0M, with ending cash of $6.6M. The balance sheet shows total assets of $8.6M, including current assets of $8.1M with $3.6M in cash and cash equivalents, $2.7M in accounts receivable, and $1.7M in inventory. Total liabilities are $2.2M, with current liabilities of $1.3M. Stockholders' equity stands at $6.4M.
The source data does not contain management guidance, strategic priorities, or specific risk factors disclosed in the filing. No forward-looking statements or outlook information is provided in the available document content or XBRL financial data.